MedTrace Logo

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07219212 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-08

No results posted yet for this study

Summary

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

JNJ-90301900

JNJ-90301900 will administered via intratumoral and/or intranodal injection.

DRUG

Cisplatin

Cisplatin will be administered intravenously.

RADIATION

Intensity Modulated Radiation Therapy (IMRT)

IMRT radiation therapy will be administered.

Sponsors & Collaborators

  • Johnson & Johnson Enterprise Innovation Inc.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Enterprise Innovation, Inc. Clinical Trial · Johnson & Johnson Enterprise Innovation Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-26
Primary Completion
2028-07-14
Completion
2028-07-14
FDA Drug
Yes

Countries

  • United States
  • France
  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07219212 on ClinicalTrials.gov